Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026)
Perrigo (PRGO) reported Other Non-Current Liabilities of $712.3 million for Q1 2026, up 31.54% year-over-year from $541.5 million in Q1 2025, and down 12.53% quarter-over-quarter from $814.3 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other Non-Current Liabilities data on file, last reported at $712.3 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $712.3 million, up 31.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $712.3 million (up 31.54% YoY), and the FY2025 annual result was $814.3 million, up 63.12% from the prior year.
- Other Non-Current Liabilities eased to $712.3 million in Q1 2026 per PRGO's latest filing, from $814.3 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $814.3 million in Q4 2025 and troughed at $499.2 million in Q4 2024.
- A 5-year average of $614.7 million and a median of $613.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities decreased 18.72% in 2024, then soared 63.12% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $623.0 million in 2022, then retreated by 10.14% to $559.8 million in 2023, then declined by 10.83% to $499.2 million in 2024, then soared by 63.12% to $814.3 million in 2025, then slipped by 12.53% to $712.3 million in 2026.
- Business Quant data shows PRGO's Other Non-Current Liabilities at $712.3 million in Q1 2026, $814.3 million in Q4 2025, and $689.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 712.30 Mn |
| Dec 31, 2025 | 814.30 Mn |
| Sep 27, 2025 | 689.70 Mn |
| Jun 28, 2025 | 673.40 Mn |
| Mar 29, 2025 | 541.50 Mn |
| Dec 31, 2024 | 499.20 Mn |
| Sep 28, 2024 | 660.30 Mn |
| Jun 29, 2024 | 535.40 Mn |
| Mar 30, 2024 | 526.20 Mn |
| Dec 31, 2023 | 559.80 Mn |
| Sep 30, 2023 | 613.90 Mn |
| Jul 1, 2023 | 658.70 Mn |
| Apr 1, 2023 | 637.60 Mn |
| Dec 31, 2022 | 623.00 Mn |
| Oct 1, 2022 | 573.20 Mn |
| Jul 2, 2022 | 577.00 Mn |
| Apr 2, 2022 | 554.20 Mn |
| Dec 31, 2021 | 530.10 Mn |
| Oct 2, 2021 | 565.80 Mn |
| Jul 3, 2021 | 554.00 Mn |